Status and phase
Conditions
Treatments
About
This is a prospective, double-blind, placebo-controlled and randomized study aimed to obtain a description of the efficacy and safety of Predimenol in alleviating headache.
Full description
Predimenol is a bioactive fraction extracted from Phaleria macrocarpa pericarpium (Mahkota Dewa).
There will be 20 subjects per group (a total of 60 subjects) planned to be enrolled in the study.
The investigational drug: tablet @200 mg of Predimenol. Dose administration: one singe dose (two tablets) of Predimenol or Placebo.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
60 participants in 3 patient groups, including a placebo group
Loading...
Central trial contact
Taruna Dibya, MD; Liana W Susanto, Pharm,MBiomed
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal